C-C Chemokine Receptor Type 5 (CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5) – Pipeline Review, H2 2017

ReportsWorldwide has announced the addition of a new report title C-C Chemokine Receptor Type 5 (CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5) – Pipeline Review, H2 2017 to its growing collection of premium market research reports.

Summary
C-C Chemokine Receptor Type 5 (CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5) pipeline Target constitutes close to 15 molecules. Out of which approximately 12 molecules are developed by companies and remaining by the universities/institutes. The latest report C-C Chemokine Receptor Type 5 - Pipeline Review, H2 2017, outlays comprehensive information on the C-C Chemokine Receptor Type 5 (CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

C-C Chemokine Receptor Type 5 (CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5) - C-C chemokine receptor type 5 (CCR5) also known as CD195, is a surface protein located on the plasma membrane of white blood cells and is encoded by CCR5 gene. This receptor binds and responds to a variety of chemokines (CCL3, CCL4, CCL5, CCL3L1). This protein is expressed by T cells and macrophages, and is known to be an important co-receptor for macrophage-tropic virus, including HIV, to enter host cells. It plays a role in granulocyte lineage proliferation and differentiation. The molecules developed by companies in Phase III, Phase II, Phase I and Preclinical stages are 2, 3, 1 and 6 respectively. Similarly, the universities portfolio in Preclinical stages comprises 3 molecules, respectively. Report covers products from therapy areas Infectious Disease, Gastrointestinal, Immunology, Oncology, Genito Urinary System And Sex Hormones, Metabolic Disorders and Musculoskeletal Disorders which include indications Human Immunodeficiency Virus (HIV) Infections (AIDS), Non-Alcoholic Steatohepatitis (NASH), Graft Versus Host Disease (GVHD), Autoimmune Disorders, Diabetic Nephropathy, Fibrosis, Kidney Fibrosis, Metastatic Colorectal Cancer, Metastatic Pancreatic Cancer, Non Alcoholic Fatty Liver Disease (NAFLD), Peritonitis, Pre-Diabetes/Impaired Glucose Tolerance, Primary Sclerosing Cholangitis and Type 2 Diabetes.

Furthermore, this report also reviews key players involved in C-C Chemokine Receptor Type 5 (CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

To Enquire about this Report please visit @ https://www.reportsworldwide.com/enquiry?report_id=41703

Scope
- The report provides a snapshot of the global therapeutic landscape for C-C Chemokine Receptor Type 5 (CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5)
- The report reviews C-C Chemokine Receptor Type 5 (CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in C-C Chemokine Receptor Type 5 (CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5) targeted therapeutics and enlists all their major and minor projects
- The report assesses C-C Chemokine Receptor Type 5 (CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to C-C Chemokine Receptor Type 5 (CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5) targeted therapeutics

Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for C-C Chemokine Receptor Type 5 (CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding C-C Chemokine Receptor Type 5 (CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

To view a detailed description and Table of Contents please visit: https://www.reportsworldwide.com/report/c-c-chemokine-receptor-type-5-chemr13-or-hiv-1-fusion-coreceptor-or-cd195-or-ccr5-pipeline-review-h2-2017

ReportsWorldwide.com is a leading provider of global market intelligence reports and services. With research reports from top publishers, consulting and advisory firms, ReportsWorldwide.com offers instant online access to a growing database of expert insights on global industries, companies, products, geographies and trends.

Press Contact:
Abigail Crasto
Senior Vice President
101, Arch Street
Boston,
MA 02110
US
Phone +1 (617) 398-1947

This release was published on openPR.